Vertex Pharmaceuticals Stock News

Biotech stocks are among the few industry groups producing breakouts and buyable stocks in an uncertain market. Vertex stock is among top biotechs to watch.

Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.

Are you reluctant to invest in stocks right now? That's understandable.

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable.

This year's top performer among the S&P 500 has been CVS Health's stock, which had a bad 2024 and is cheap by a key valuation measure.

When you're on an airplane, the pilot or a flight attendant will typically announce over the loudspeaker to "buckle your seatbelt" when the air is turbulent. That could be good advice for investors right now, too.

The past decade has been a game-changing one for Vertex Pharmaceuticals (VRTX 2.40%). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Leerink's Global Healthcare Conference 2025 March 10, 2025 10:00 AM ET Company Participants Charlie Wagner - CFO and COO David Altshuler - Chief Scientific Officer Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger Great. Well thanks very much, everyone, for joining us for our next session with Vertex.